Viatris VTRS
Viatris FY 2022: revenue $16.3B, down 9%; diluted EPS $1.71
- Form
- 10-K/A
- Filed
- Period
- Importance
- Routine
- Accession
- 0001193125-23-127172
- Document
- 10-K/A
Key figures from this report
These are the numbers Viatris reported for the year ended Dec 31, 2022, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$16.3B−9% from $17.9B in FY 202110-K income statement, on EDGAR
- Diluted EPS$1.71Against −$1.05 in FY 202110-K income statement, on EDGAR
- Cash and cash equivalents$1.3B+80% from $701.2M in FY 2021Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations$3.0B−2% from $3.0B in FY 202110-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Roivant Sciences ROIV public float $9.8B, Sep 30, 2025
- United Therapeutics UTHR public float $11.2B, Jun 30, 2025
- Neurocrine Biosciences NBIX public float $9.5B, Jun 30, 2025
- Exelixis EXEL public float $9.4B, Jul 4, 2025
- BIO-TECHNE TECH public float $9.1B, Dec 31, 2025
